KPV is a tiny three amino acid peptide (lysine, proline, valine) used to calm inflammation without shutting the immune system down the way steroids do. Most people take it for gut problems (IBD, ulcerative colitis, Crohn's, IBS, leaky gut, NSAID damage) where it can be dosed orally, or for inflammatory skin conditions like eczema, psoriasis, and acne where it's applied topically. A smaller group uses it as a general anti-inflammatory alongside other recovery peptides like BPC-157 and TB-500 (Thymosin Beta-4).
It is unique in two ways. First, it can be taken by mouth, which is rare for a peptide since most get destroyed by stomach acid. Second, it works precisely where inflammation is happening, the transporter that pulls KPV into cells (PepT1) is barely expressed in healthy gut tissue but heavily upregulated in inflamed gut tissue, so the peptide self-targets the damaged areas and largely ignores the rest. The catch is that the entire human evidence base is preclinical. There are no completed randomised controlled trials in people, so dosing comes from animal studies and community practice rather than clinical guidelines.
Deep-dive
KPV is the C-terminal fragment (positions 11 to 13) of alpha-melanocyte-stimulating hormone (α-MSH), the larger 13 amino acid hormone that regulates skin pigmentation, appetite, and immune tone. α-MSH is one of the body's natural anti-inflammatory signals, and a series of truncation studies in the 1990s and 2000s established that the anti-inflammatory activity sits almost entirely in those last three residues. The KPV fragment retains the parent hormone's ability to suppress inflammation but doesn't activate the melanocortin receptors that drive tanning, libido, or appetite changes. This is the practical reason it gets used instead of α-MSH itself: same anti-inflammatory effect, none of the pigment, sexual, or appetite side effects you get from related peptides like Melanotan II or PT-141.
How it works at the cell level. The foundational mechanistic paper is Dalmasso et al. 2008 in Gastroenterology. They showed that KPV at nanomolar concentrations enters intestinal epithelial cells and macrophages through the PepT1 (peptide transporter 1) transporter, the same one your gut uses to absorb dietary di- and tripeptides. Once inside the cell, KPV blocks activation of two master inflammatory signalling pathways: NF-κB (the transcription factor that drives production of TNF-α, IL-6, IL-1β, IL-8, and most of the cytokines that sustain chronic inflammation) and the MAP kinase pathway. The net effect is broad downregulation of inflammatory gene transcription. A 2008 paper by Kannengiesser et al. showed this anti-inflammatory action is independent of melanocortin receptors, confirming KPV works through an intracellular pathway distinct from how the full α-MSH hormone operates.
Why PepT1 matters. PepT1 is barely expressed in healthy colonic epithelium but is strongly upregulated in inflamed bowel tissue and in colorectal tumours. This means KPV concentrates exactly where it's needed and leaves healthy tissue alone, what some researchers call "disease-state bioavailability." The same study fed KPV in drinking water to mice with chemically induced colitis (DSS and TNBS models) and found it reduced disease severity, with PepT1-knockout mice losing the benefit entirely.
Gut inflammation and colitis-associated cancer. The strongest preclinical signal is in the gut. Viennois et al. 2016 in Cellular and Molecular Gastroenterology and Hepatology found that KPV not only reduced colonic inflammation in mice but also lowered the incidence of colitis-associated colorectal cancer in animals with overexpressed PepT1. In PepT1-knockout mice the protective effect disappeared, confirming the transporter-dependent mechanism. Several groups have since built KPV-loaded nanoparticles to improve colonic targeting, with a 2017 hyaluronic acid nanoparticle paper showing better mucosal healing and TNF-α suppression than free KPV in mouse ulcerative colitis. The translation to humans hasn't happened. No randomised trial in IBD patients has been completed.
Skin and wound healing. KPV in topical or local form has been studied for inflammatory skin disease and wound repair. A 2025 paper in HaCaT keratinocytes showed 50 μg/mL KPV restored cell viability and lowered IL-1β secretion after fine particulate matter exposure by acting on the same NF-κB and MAPK pathways. Brzoska, Luger and colleagues' 2008 Endocrine Reviews paper summarises decades of work showing α-MSH and KPV reduce inflammation in models of contact dermatitis, atopic dermatitis, and psoriasis, and modulate the keratinocyte and immune cell signalling that drives those conditions. The honest limitation: KPV doesn't penetrate intact skin very well. Iontophoresis or microneedling can boost transdermal delivery up to 35-fold, but standard creams deliver limited concentrations. Most over-the-counter cosmetic products that list KPV probably aren't getting therapeutic doses into the dermis.
Antimicrobial activity. Cutuli et al. 2000 in the Journal of Leukocyte Biology showed KPV and α-MSH inhibit colony formation of Staphylococcus aureus and Candida albicans across a wide concentration range, including physiological picomolar levels. The mechanism involves increasing cAMP in the target organisms. This is part of why it's interesting for skin conditions that involve overgrowth of these particular pathogens (Candida-driven dermatitis, S. aureus colonisation in eczema, fungal acne) and for gut conditions involving Candida overgrowth. The data is all in vitro or animal, no human antifungal trials exist.
Systemic and other applications. Beyond gut and skin, KPV has been studied in animal models of peritonitis, arthritis, asthma, and brain inflammation. The 2003 Getting et al. peritonitis study showed the three amino acid fragment reduced inflammatory cell migration roughly as effectively as the full 13 amino acid α-MSH, which is what first established the C-terminal as the active piece. A subset of users report subjective benefits for histamine-driven symptoms (mast cell activation, allergic flushing), brain fog associated with chronic inflammation, and post-viral fatigue. These claims are anecdotal and not supported by trial data, but the underlying mechanism (broad NF-κB suppression and mast cell stabilisation by α-MSH-family peptides) is plausible.
Women. IBD epidemiology skews mildly female for Crohn's and is roughly even for ulcerative colitis, with women showing longer diagnostic delays and higher rates of misdiagnosis. Inflammatory skin conditions like eczema and rosacea are also more prevalent in women. The mechanism of KPV is not sex-specific, it acts on PepT1 and NF-κB in the same way regardless of hormonal status, and animal studies in DSS colitis have included female mice and shown comparable benefit (with females actually showing slightly less severe baseline colitis than males in some models). No female-specific dose adjustment is needed. KPV does not affect oestrogen, progesterone, the HPA axis, or thyroid function, so there's no expected interaction with hormonal contraception, HRT, or menstrual cycle. Skip it in pregnancy and breastfeeding, no safety data exists in those populations.
Limitations of the evidence. Almost everything good ever written about KPV comes from preclinical work. No completed human RCT exists. The doses people use today are extrapolations from mouse studies plus community practice. There's also publication bias to consider, negative findings in this peptide space tend not to get published, so the evidence may look more uniformly positive than it actually is. The molecule is plausible, the mechanism is well-characterised, the safety signal in animals is excellent, but the gap between "works in mice" and "works in humans" is real and has killed many promising peptides.
Dosage:
- Oral (gut conditions, systemic anti-inflammatory): 250 to 500 mcg once or twice daily, on an empty stomach, 20 to 30 minutes before food. Most people land at 500 mcg twice daily for an active IBD flare or significant gut symptoms, and 250 to 500 mcg once daily for milder issues or maintenance. Some protocols go up to 1 mg/day but there's no signal this works better than the standard range
- Subcutaneous (systemic, joint inflammation, skin from the inside, mast cell symptoms): 250 to 500 mcg once daily, occasionally split into two doses. Inject anywhere you'd normally inject a peptide (abdomen, thigh). Site doesn't matter much since KPV works systemically
- Topical (localised skin conditions): 0.1 to 1% concentration in a cream, serum, or ointment, applied twice daily to the affected area. For deeper penetration on stubborn lesions, micro-needling or dermarolling beforehand significantly improves delivery
- Cycle length: 4 to 8 weeks is the typical run, with reassessment afterwards. Cycling isn't mechanistically required (no receptor downregulation, no tolerance) but most people don't need it indefinitely. For chronic IBD or recurrent conditions, longer continuous use at lower doses is reasonable
- Stacks: Frequently combined with BPC-157 for gut healing, the two work on different parts of the cascade (BPC-157 drives angiogenesis and tissue repair, KPV calms the inflammatory signalling). Also stacked with TB-500 (Thymosin Beta-4) for systemic recovery. When stacking, run KPV at the lower end of the range (250 to 500 mcg) to avoid piling anti-inflammatory load on top of itself
- Storage: Lyophilised KPV is stable at room temperature for short periods, in a fridge for longer. Once reconstituted with bacteriostatic water, refrigerate and use within 30 days. Typical reconstitution is 10 mg in 2 mL of bacteriostatic water, giving 5,000 mcg/mL (so 0.05 mL = 250 mcg, 0.1 mL = 500 mcg)
- No hormonal interactions. Does not affect oestrogen, progesterone, testosterone, the HPA axis, or thyroid. No female-specific dose adjustment needed. Avoid in pregnancy and breastfeeding
Here's what you can expect:
For gut conditions (the strongest use case): a meaningful reduction in bloating, cramping, urgency, and stool frequency is commonly reported within 1 to 3 weeks. For more structural issues like NSAID damage or chronic mucosal inflammation, 4 to 8 weeks gives the lining time to actually heal. People with IBD-pattern symptoms (alternating diarrhoea and constipation, post-meal cramping, food sensitivity) tend to report the clearest changes. Anecdotally, KPV does well for the inflammation-driven gut symptoms but doesn't fix issues that are primarily motility, microbiome, or structural in nature.
For skin conditions (topical): visible reduction in redness and flare intensity within 2 to 4 weeks of consistent application. Eczema, contact dermatitis, and rosacea tend to respond before psoriasis. Penetration is the limiting factor for topical use, results from a basic cream are modest compared to delivery via micro-needling or iontophoresis.
For systemic use (subcutaneous): subtle. Some people notice reduced joint stiffness, less reactivity to foods or environmental triggers, calmer skin, and a general sense of "less inflamed" within 2 to 4 weeks. Others notice nothing distinct. Subjective effect is less predictable than the gut or topical routes because there's no acute load on the system to compare against.
KPV is not a fast-acting compound. It doesn't produce a noticeable effect after a single dose the way a stimulant or anxiolytic might. Run it for at least 4 weeks at a real dose before deciding whether it works for you.
Side effects & risks:
- Excellent tolerability across animal and limited human exposure. Animal toxicology shows no organ toxicity even at very high doses. No lethal dose has been established. The few small human case series and clinical experience from compounding pharmacies report nothing serious
- Mild nausea or GI upset at higher oral doses, particularly on an empty stomach. Splitting the dose or taking with a small amount of food usually resolves it without meaningfully reducing absorption
- Injection site reactions with subcutaneous use: redness, mild tenderness, occasional small bumps. Rotating sites reduces this
- Headache and lightheadedness are reported occasionally, usually at higher doses and resolving with dose reduction
- No hormonal effects. Does not affect testosterone, oestrogen, cortisol, thyroid, or the HPG axis. Does not cause tanning, libido changes, or appetite suppression unlike its parent hormone family. This is a clean profile relative to other melanocortin-related peptides
- No documented drug interactions. KPV doesn't go through CYP enzymes and doesn't displace anything significant from plasma binding
- Pregnancy and breastfeeding, avoid. No safety data exists in these populations
- Active cancer, caution and discuss with your oncologist. PepT1 is upregulated in colorectal and some other tumours, which is why KPV self-targets to those cells. In animal IBD models this was protective and reduced tumour incidence, but the broader question of how KPV interacts with established cancer hasn't been answered. The safest position if you have active cancer is to avoid it until more data exists
- Source quality matters. KPV is sold extensively as a research chemical with widely variable purity. Always ask for a recent third-party Certificate of Analysis confirming identity, purity, and concentration. Counterfeit and underdosed products are a real problem in this market
- No completed human clinical trial. Everything in this section is extrapolation from animal data plus user experience. The actual long-term safety profile in humans at the doses being used is genuinely unknown. The compound looks safe based on what we have, but "looks safe" is not the same as "has been shown to be safe in a large human trial"
Blood markers
CRP (C-reactive protein) and ESR, baseline and at 8 to 12 weeks if you're using KPV for a systemic inflammatory condition. These are the cheapest, most general inflammation markers and the ones most likely to move if the peptide is doing what you want.
Faecal calprotectin, baseline and at 8 to 12 weeks if you're using oral KPV for IBD or significant gut symptoms. This is the gold-standard marker for gut-specific inflammation and will tell you more than systemic markers whether the gut lining is actually calming down.
CBC and CMP (complete blood count and comprehensive metabolic panel), baseline as standard before starting any new injectable peptide and at 12 weeks for chronic use. No specific KPV-driven changes are expected, but you want a reference point
Liver enzymes (ALT, AST) as part of the CMP. KPV is not known to be hepatotoxic but long-term peptide use at meaningful doses is understudied
No need to track hormonal markers, KPV doesn't move testosterone, oestrogen, cortisol, or thyroid. For most people using KPV short-term at standard doses, CRP and (if relevant) faecal calprotectin are the two markers that actually matter.
KPV is not approved for human use by any regulatory body. The FDA classified it as a 503A Category 2 bulk drug substance in 2023, restricting compounding pharmacies. In April 2026, FDA removed KPV from Category 2, and the Pharmacy Compounding Advisory Committee is scheduled to review it for inclusion on the 503A Bulks List at meetings on July 23 to 24, 2026, alongside BPC-157, TB-500, and MOTs-C. Outcome is pending.